Viswanath Arutla

Characterization of a highly specific NQO1-activated near-infrared fluorescent probe and its application for in vivo tumor imaging

Surendra R. Punganuru, Hanumantha Rao Madala, Viswanath Arutla et al. · Scientific Reports · 2019 · 44 citations · Full text

Medicine, Oncology, Pharmacology +17

Cancer-Specific Biomarker hNQO1-Activatable Fluorescent Probe for Imaging Cancer Cells In Vitro and In Vivo

Surendra R. Punganuru, Hanumantha Rao Madala, Viswanath Arutla et al. · Cancers · 2018 · 23 citations · Full text

Medicine, Cancer Biology, Molecular Biology +17

Conception, synthesis, and characterization of a rofecoxib-combretastatin hybrid drug with potent cyclooxygenase-2 (COX-2) inhibiting and microtubule disrupting activities in colon cancer cell culture and xenograft models

Surendra R. Punganuru, Hanumantha Rao Madala, Constantinos M. Mikelis et al. · Oncotarget · 2018 · 22 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action

Surendra R. Punganuru, Viswanath Arutla, Wei Zhao et al. · Cells · 2020 · 20 citations · Full text

Medicine, Oncology, Pharmacology +17

RETRACTED: Selective killing of human breast cancer cells by the styryl lactone (R)-goniothalamin is mediated by glutathione conjugation, induction of oxidative stress and marked reactivation of the R175H mutant p53 protein

Surendra R. Punganuru, Hanumantha Rao Madala, Viswanath Arutla et al. · Carcinogenesis · 2018 · 13 citations · Full text

Life Sciences, Oncology, Pharmacology +17